-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$28.297.12% Upside
Myriad Genetics, Inc. Frequently Asked Questions
-
What analysts cover Myriad Genetics, Inc.?
Myriad Genetics, Inc. has been rated by research analysts at Morgan Stanley, Wells Fargo, Guggenheim, Scotiabank, Piper Sandler, Stephens in the past 90 days.